Search

Your search keyword '"Zhi L. Teo"' showing total 12 results
Start Over Author "Zhi L. Teo" Database OpenAIRE
12 results on '"Zhi L. Teo"'

1. Supplementary Table 3 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

Author

David E. Goldgar, Melissa C. Southey, Sean V. Tavtigian, Fabienne Lesueur, Bing-Jian Feng, John L. Hopper, Graham G. Giles, Peter Devilee, Henry T. Lynch, Carrie Snyder, Saundra S. Buys, Mary Daly, Mary B. Terry, Irene L. Andrulis, Esther M. John, Igor V. Makunin, Jun Li, Jonathan Ellis, Chad D. Huff, Hao Hu, Russell Bell, Terrell C. Roane, Bernard J. Pope, Andrew Lonie, Catherine Voegele, Erin L. Young, Louise B. Thingholm, Zhi L. Teo, Helen Tsimiklis, Fabrice Odefrey, Fleur Hammet, Nivonirina Robinot, Tu Nguyen-Dumont, Florence Le Calvez-Kelm, Kayoko Tao, and Daniel J. Park

Abstract

PDF file 65K, Primers used in assessment of RINT1 transcripts

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 1 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

Author

David E. Goldgar, Melissa C. Southey, Sean V. Tavtigian, Fabienne Lesueur, Bing-Jian Feng, John L. Hopper, Graham G. Giles, Peter Devilee, Henry T. Lynch, Carrie Snyder, Saundra S. Buys, Mary Daly, Mary B. Terry, Irene L. Andrulis, Esther M. John, Igor V. Makunin, Jun Li, Jonathan Ellis, Chad D. Huff, Hao Hu, Russell Bell, Terrell C. Roane, Bernard J. Pope, Andrew Lonie, Catherine Voegele, Erin L. Young, Louise B. Thingholm, Zhi L. Teo, Helen Tsimiklis, Fabrice Odefrey, Fleur Hammet, Nivonirina Robinot, Tu Nguyen-Dumont, Florence Le Calvez-Kelm, Kayoko Tao, and Daniel J. Park

Abstract

PDF file 199K, RINT1 c.1334-5delA, c.1334-1_1335delGTT minigene assay

Published
2023
Full Text
View/download PDF

3. Supplementary Table 1 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers

Author

David E. Goldgar, Melissa C. Southey, Sean V. Tavtigian, Fabienne Lesueur, Bing-Jian Feng, John L. Hopper, Graham G. Giles, Peter Devilee, Henry T. Lynch, Carrie Snyder, Saundra S. Buys, Mary Daly, Mary B. Terry, Irene L. Andrulis, Esther M. John, Igor V. Makunin, Jun Li, Jonathan Ellis, Chad D. Huff, Hao Hu, Russell Bell, Terrell C. Roane, Bernard J. Pope, Andrew Lonie, Catherine Voegele, Erin L. Young, Louise B. Thingholm, Zhi L. Teo, Helen Tsimiklis, Fabrice Odefrey, Fleur Hammet, Nivonirina Robinot, Tu Nguyen-Dumont, Florence Le Calvez-Kelm, Kayoko Tao, and Daniel J. Park

Abstract

PDF file 69K, Distribution of cases and controls included in the analysis, by study center and ethnic group

Published
2023
Full Text
View/download PDF

4. Figure S4 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Figure S4 shows the effect of CXCR3 blockade on the number and phenotype of tumor-infiltrating immune cells post combination therapy

Published
2023
Full Text
View/download PDF

5. Data from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Purpose:Response rates to immune checkpoint blockade (ICB; anti-PD-1/anti-CTLA-4) correlate with the extent of tumor immune infiltrate, but the mechanisms underlying the recruitment of T cells following therapy are poorly characterized. A greater understanding of these processes may see the development of therapeutic interventions that enhance T-cell recruitment and, consequently, improved patient outcomes. We therefore investigated the chemokines essential for immune cell recruitment and subsequent therapeutic efficacy of these immunotherapies.Experimental Design:The chemokines upregulated by dual PD-1/CTLA-4 blockade were assessed using NanoString-based analysis with results confirmed at the protein level by flow cytometry and cytometric bead array. Blocking/neutralizing antibodies confirmed the requirement for key chemokines/cytokines and immune effector cells. Results were confirmed in patients treated with immune checkpoint inhibitors using single-cell RNA-sequencing (RNA-seq) and paired survival analyses.Results:The CXCR3 ligands, CXCL9 and CXCL10, were significantly upregulated following dual PD-1/CTLA-4 blockade and both CD8+ T-cell infiltration and therapeutic efficacy were CXCR3 dependent. In both murine models and patients undergoing immunotherapy, macrophages were the predominant source of CXCL9 and their depletion abrogated CD8+ T-cell infiltration and the therapeutic efficacy of dual ICB. Single-cell RNA-seq analysis of patient tumor-infiltrating lymphocytes (TIL) revealed that CXCL9/10/11 was predominantly expressed by macrophages following ICB and we identified a distinct macrophage signature that was associated with positive responses to ICB.Conclusions:These data underline the fundamental importance of macrophage-derived CXCR3 ligands for the therapeutic efficacy of ICB and highlight the potential of manipulating this axis to enhance patient responses.

Published
2023
Full Text
View/download PDF

6. Supplementary Figure Legends from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Supplementary Figure Legends

Published
2023
Full Text
View/download PDF

7. Figure S7 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Figure S7 shows the gene expression profile of macrophages and other immune cell subsets in cancer patients

Published
2023
Full Text
View/download PDF

8. Figure S2 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Figure S2 shows the expression of chemokines following single agent anti-PD-1 therapy in patients and their association with patient prognosis and immune cell infiltrate.

Published
2023
Full Text
View/download PDF

9. Figure S6 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Figure S6 shows the phenotype and expression of CXCL9 and CXCL10 by tumor-infiltrating immune cells following treatment with anti-PD-1 and anti-CTLA-4

Published
2023
Full Text
View/download PDF

10. Figure S5 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Figure S5 shows the expression of CXCL9 and CXCL10 mRNA and protein by AT-3ova tumor cells following stimulation with IFNgamma and TNFalpha

Published
2023
Full Text
View/download PDF

11. Figure S3 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Figure S3 shows the association between the expression of chemokines/ chemokine receptors and patient prognosis and immune cell infiltrate.

Published
2023
Full Text
View/download PDF

12. Figure S1 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Author

Paul A. Beavis, Phillip K. Darcy, Sherene Loi, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Camelia Quek, Tuba N. Gide, Sherly Mardiana, Kevin Sek, Emma V. Petley, Lauren Giuffrida, Melissa A. Henderson, Kirsten L. Todd, Zhi L. Teo, Amanda J. Oliver, Amanda X.Y. Chen, Junyun Lai, Peter Savas, and Imran G. House

Abstract

Figure S1 shows the response of AT-3 ova tumors to single agent anti-PD-1 or anti-CTLA-4 and the upregulation of chemokine receptors or chemokines following dual or single agent therapy.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results